The Phase 2 trial of VTX958 in Crohn’s disease did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group Both VTX958 dose groups achieved nominal...
Ventyx Biosciences’ Crohn’s disease medicine did not help patients achieve remission in a phase 2 trial, sending the California biotech’s shares down over 20% at the open of Monday trading.
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences